Literature DB >> 8995501

Electropermeabilization in bladder cancer chemotherapy.

Y Kubota1, T Nakada, H Yanai, H Kakizaki, I Sasagawa, M Watanabe.   

Abstract

PURPOSE: Electropermeabilization has been used for the introduction of genes into cells. Using this technique, we introduced the cytotoxic drug bleomycin (BLM) into cells and examined whether the technique might be useful for the treatment of bladder cancer.
MATERIALS AND METHODS: For electropermeabilization in vitro, we used YTS-1 cells, a human transitional cell carcinoma line. Aliquots of cell suspension were mixed with a solution of BLM and immediately exposed to electric pulses. A high-power pulse generator was used to supply square-shaped pulses of 1250 V/cm (100 micros, eight pulses). After a 2-h post-shock incubation, cells were washed and incubated for one further hour. Then the concentration of BLM in the cells was measured using a bioassay. For electropermeabilization of tissue, we used normal male Wistar rats. The bladder was exposed and 10 mg/kg BLM was injected into the caudal vein. A series of eight pulses with a time constant of 100 micros at an electric field intensity of 1000 V/cm was applied. The bladder, liver and lungs were extracted 1 h later and prepared for quantification of the BLM concentration using the bioassay.
RESULTS: Electrotreated cells contained significantly higher concentrations of BLM than nonelectrotreated cells. The concentration of BLM 1 h after electrotreatment in bladder tissue was 2.7 times higher than that in nonelectrotreated bladder tissue.
CONCLUSION: The electropermeabilization technique has the potential to serve as a new and effective modality for the treatment of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8995501     DOI: 10.1007/s002800050539

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

1.  The role of LIM and SH3 protein-1 in bladder cancer metastasis.

Authors:  Misaki Sato; Mihoko Sutoh Yoneyama; Shingo Hatakeyama; Tomihisa Funyu; Tadashi Suzuki; Chikara Ohyama; Shigeru Tsuboi
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

2.  MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.

Authors:  Yuichiro Suzuki; Mihoko Sutoh; Shingo Hatakeyama; Kazuyuki Mori; Hayato Yamamoto; Takuya Koie; Hisao Saitoh; Kanemitsu Yamaya; Tomihisa Funyu; Tomonori Habuchi; Yoichi Arai; Minoru Fukuda; Chikara Ohyama; Shigeru Tsuboi
Journal:  Int J Oncol       Date:  2012-03-23       Impact factor: 5.650

3.  A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans.

Authors:  Shigeru Tsuboi; Mihoko Sutoh; Shingo Hatakeyama; Nobuyoshi Hiraoka; Tomonori Habuchi; Yohei Horikawa; Yasuhiro Hashimoto; Takahiro Yoneyama; Kazuyuki Mori; Takuya Koie; Toshiya Nakamura; Hisao Saitoh; Kanemitsu Yamaya; Tomihisa Funyu; Minoru Fukuda; Chikara Ohyama
Journal:  EMBO J       Date:  2011-06-28       Impact factor: 11.598

4.  Enhanced efficacy of bleomycin in bladder cancer cells by photochemical internalization.

Authors:  Yan Baglo; Lars Hagen; Anders Høgset; Finn Drabløs; Marit Otterlei; Odrun A Gederaas
Journal:  Biomed Res Int       Date:  2014-06-30       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.